Novo Nordisk A/S (NVO)vs Pfizer Inc. (PFE)

Quick verdict

Novo Nordisk A/S (NVO) and Pfizer Inc. (PFE) appeal to different investors. On our six-factor framework, NVO scores 2.5 and PFE scores 3.5. PFE looks cheaper on the multiples that matter, while NVO grows faster and neither clearly earns higher returns on capital. Overall, PFE edges this comparison, but the right pick depends on whether you prioritise value, growth, income or balance-sheet safety.

2-year relative performance

At-a-glance comparison

Business model and revenue mix

Novo Nordisk A/S operates in Drug Manufacturers (Healthcare), while Pfizer Inc. sits in Drug Manufacturers - General (Healthcare). Because both compete in the same sector, this is a direct head-to-head and the financial differences below are especially meaningful. NVO carries a beta of 1.80 versus 0.31 for PFE, meaning NVO has historically been the more volatile of the two.

Valuation

On valuation, PFE is the cheaper stock. NVO trades on a forward P/E of 31.06 and EV/EBITDA of 30.66, against 12.65 and 16.58 for PFE. Price-to-sales is 17.63 vs 2.31, and free-cash-flow yield is 5.8% vs 1.0%. A higher multiple is only justified if the company can sustain faster growth or wider margins, which is exactly what the next sections test.

Growth profile

NVO is the faster grower. NVO has compounded revenue at 13.2% over three years with EPS growth of 10.4%, while PFE has delivered -1.6% revenue and -4.2% EPS growth. Growth like this is the single biggest driver of long-term returns, but it also tends to come with a richer valuation, so it must be weighed against the multiples above.

Profitability and quality

On profitability and quality, neither clearly is stronger. NVO posts a 12.9% operating margin, 17.3% return on equity and 30.2% return on invested capital. PFE posts 25.1%, 4.9% and 9.3% respectively. Return on invested capital above roughly 15% is a hallmark of a durable competitive advantage, so this metric deserves particular attention.

Balance-sheet risk

PFE has the safer balance sheet. NVO carries net-debt/EBITDA of 4.18x with a current ratio of 2.55, versus 1.53x and 1.27 for PFE. Lower leverage gives a company more room to invest through a downturn and reduces the risk of dilution or distress.

Price performance and shareholder returns

Over the past year NVO returned 76.3% against 85.4% for PFE; on a three-year annualised basis it is 30.4% vs -3.0%. NVO yields 0.0% and PFE yields 6.7%. Past performance never guarantees future results, but the multi-year track record shows how the market has rewarded each business so far.

Which stock fits which investor

For value-oriented investors, PFE is the better fit on today's multiples. Growth investors will likely prefer NVO, which is expanding faster. Income investors should lean toward PFE for its higher shareholder yield, while investors who prize quality-at-a-reasonable-price will favour NVO for its superior returns on capital. This is a comparison of facts, not a recommendation — your time horizon, risk tolerance and existing holdings should drive the final decision.

• Value: PFE
• Growth: NVO
• Income: PFE
• Quality: NVO

Frequently asked questions

Is NVO or PFE the better buy right now?

Neither is universally "better." NVO scores 2.5 and PFE scores 3.5 on our six-factor framework. PFE is cheaper, NVO grows faster, and neither clearly is higher quality — so the right pick depends on your objective.

Which stock is cheaper, NVO or PFE?

PFE is the cheaper stock across forward P/E (31.06 vs 12.65), EV/EBITDA (30.66 vs 16.58) and price-to-sales (17.63 vs 2.31).

Which has grown faster, NVO or PFE?

NVO has the stronger growth profile, with three-year revenue CAGR of 13.2% for NVO versus -1.6% for PFE.

Which stock pays a bigger dividend?

NVO yields 0.0% and PFE yields 6.7%, so PFE is the stronger income choice.

Related comparisons

• AAPL vs NVO
• AMZN vs NVO
• LLY vs NVO
• LLY vs PFE
• NVDA vs NVO
• NVO vs UNH